- Werfen enters into an settlement to purchase Immucor, Inc., a privately held, US-based company, with a stable world presence in transfusion and transplant in vitro diagnostics
- The transaction is anticipated to shut through the first half of 2023
BARCELONA, Spain, Nov. 3, 2022 /PRNewswire/ — Werfen introduced at present that it has agreed to purchase Immucor, Inc., from TPG. Immucor is a privately held company with a robust world presence in transfusion and transplant in vitro diagnostics, headquartered in Norcross, Georgia, USA. This acquisition will enable Werfen to broaden its portfolio of Specialized Diagnostics options for hospitals and scientific laboratories.
The buy worth is anticipated to be roughly US$2 billion, with closing topic to customary regulatory approvals. The acquisition is being funded with a mixture of money readily available and new senior credit score amenities. The firm doesn’t anticipate the transaction to impression its funding grade ranking from Standard & Poor’s.
“As a global leader in the research, development, manufacturing and distribution of innovative, Specialized Diagnostics solutions for hospitals and clinical laboratories, Immucor is a natural fit with our existing business model,” mentioned Marc Rubiralta, President of Werfen. “We highly value Immucor’s commitment to enhancing care for all patients in need of a transfusion or transplant. This fits squarely with our long-term vision and strategy, aligns with our focus, and complements Werfen’s values.”
Rubiralta added, “I am confident that by combining two complementary, outstanding Specialized Diagnostics companies, Werfen will expand its global presence with greater diversification, while successfully maintaining its focus on specialization.”
“Immucor’s expertise and innovations in transfusion and transplant diagnostics enable us to enter new markets and will help achieve our vision to be the preferred choice of the most advanced laboratory and point-of-care customers, globally,” mentioned Carlos Pascual, CEO of Werfen. “It will be a major milestone in the future of Werfen.”
Avi Pelossof, CEO of Immucor mentioned, “As we look to the future, we are excited to grow our impact as part of Werfen, a company that shares our long-term vision and commitment to advancing patient care globally. As the value of diagnostics in the healthcare system grows, we are confident that Immucor will continue to innovate and succeed under Werfen’s ownership.”
Upon completion of this acquisition, and primarily based on 2021 figures, Werfen will surpass €2.2 billion in income, with seven know-how facilities, shut to 7,000 workers worldwide, and a direct presence in 30 international locations and greater than 100 territories by means of distributors.
Werfen was suggested by Barclays and Milbank LLP. BBVA, BNP Paribas, CaixaBank and HSBC Holding plc supplied commitments for the brand new senior credit score amenities. The sellers and Immucor have been suggested by Evercore and Ropes & Gray LLP.
Founded in 1966, Werfen is a worldwide developer, producer and distributor of Specialized Diagnostic devices, associated reagents, automation workcells, and information administration options to be used primarily in hospitals and unbiased scientific laboratories. The Company’s business models embody Hemostasis, Acute Care Diagnostics, Autoimmunity, and Original Equipment Manufacturing (OEM). Werfen operates straight in almost 30 international locations and in greater than 100 territories by means of distributors. For extra data, go to werfen.com
TPG is a number one world different asset administration agency, based in San Francisco in 1992, with $127 billion of belongings below administration and funding and operational groups in 12 places of work globally. TPG invests throughout 5 multi-product platforms: Capital, Growth, Impact, Real Estate, and Market Solutions and our distinctive technique is pushed by collaboration, innovation, and inclusion. Our groups mix deep product and sector expertise with broad capabilities and experience to develop differentiated insights and add worth for our fund traders, portfolio firms, administration groups, and communities. For extra data go to www.tpg.com or @TPG on Twitter.
This doc comprises forward-looking statements about our business, monetary information, and occasions associated to the prospects of Werfen. These forecasts will be recognized by means of phrases similar to “expectation”, “vision”, “anticipation”, “intention”, “plan”, “belief”, “search”, “estimate”, “future”, “project”, or phrases with an identical that means. We can also make projections in different experiences, shows, and press releases. Furthermore, our gross sales representatives could sometimes make forward-looking statements. These projections are primarily based on our present expectations and on sure hypotheses, a lot of that are past the company’s management and topic to a collection of dangers and uncertainties. In the occasion that any of those dangers or uncertainties ought to materialize or the underlying expectations aren’t fulfilled, the outcomes or efficiency of Werfen could differ considerably (both positively or negatively) from these explicitly or implicitly forecast. Werfen assumes no obligation to replace or revise any forward-looking statements made beforehand.
Photo – https://mma.prnewswire.com/media/1937701/Werfen_President_Marc_Rubiralta.jpg
Logo – https://mma.prnewswire.com/media/1561045/Werfen_Logo.jpg
View authentic content material:https://www.prnewswire.co.uk/news-releases/werfen-to-acquire-immucor-inc-expanding-its-presence-in-specialized-diagnostics-301668259.html
